Infectious clones of RNA viruses and vaccines and diagnostic assays derived thereof

• US 6,268,199 B1
• Filed: 10/12/1999
• Issued: 07/31/2001
• Est. Priority Date: 10/30/1996
• Status: Expired due to Term

• Current Assignee: Boehringer Ingelheim Vetmedica GmbH (C.H. Boehringer Sohn AG & Co. KG)
• Original Assignee: Stichting Dienst Landbouwkundig Onderzoek
• Inventors: Meulenberg, Johanna Jacoba Maria, Pol, Johannes Maria Antonius, Bos-de Ruijter, Judy Norma Aletta
• Primary Examiner(s): Stucker, Jeffrey
• Assistant Examiner(s): JENKS, ULRIKE WINKLER
• Application Number:
  US09/297,535
• Time in Patent Office: 658 Days
• Field of Search: 424/184.1, 424/204.1, 424/221.1, 424/815, 435/5, 435/69.3, 435/91.1, 435/235--23, 435/252.3, 435/335, 530/350, 536/23.72, 536/23.1
• US Class Current: 435/235.1
• CPC Class Codes: A61K 39/00 Medicinal preparations containing antigens or antibodies materials for immunoassay G01N33/53
• CPC Class Codes: A61P 37/04 Immunostimulants
• CPC Class Codes: C07K 14/005 from viruses
• CPC Class Codes: C12N 2770/10022 New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
• CPC Class Codes: C12N 2770/10034 Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
• CPC Class Codes: C12N 7/00 Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof preparing medicinal viral antigen or antibody compositions, e.g. virus vaccines, A61K39/00

Abstract

An infectious clone based on the genome of a wild-type RNA virus is produced by the process of providing a host cell not susceptible to infection by the wild-type RNA virus, providing a recombinant nucleic acid based on the genome of the wild-type RNA virus, transfecting the host cell with the recombinant nucleic acid and selecting for infectious clones. The recombinant nucleic acid comprises at least one full-length DNA copy or in vitro-transcribed RNA copy or a derivative of either. The infectious clones can be used in single or dual purpose vaccines and in viral vector vaccines.

Claims

1. An infectious clone based on a genome of a RNA virus comprising a PRRS virus, said infectious clone generated by a process comprising:

providing a host cell not susceptible to infection by a wild-type of said RNA virus;

providing a recombinant nucleic acid based on the genome of said RNA virus, said recombinant nucleic acid comprising at least one full-length DNA copy or in vitro-transcribed RNA copy or a derivative of either;

transfecting said host cell with said recombinant nucleic acid; and

selecting for infectious clones.

2. The infectious clone of claim 1, wherein said recombinant nucleic acid comprises at least one nucleic acid sequence encoding a virulence marker and/or a serological marker particular to said wild-type RNA virus, and wherein said at least one nucleic acid sequence has been modified by cloning techniques to effect a change in virulence and/or a change in serological immune response in vivo.

3. The infectious clone of claim 2 wherein the nucleic acid sequence encoding said virulence and/or serological marker or markers is located within any open reading frames encoding structural viral proteins.

4. The infectious clone of claim 3 wherein one of said open reading frames is ORF7.

5. The infectious clone of claim 1 wherein said recombinant nucleic acid comprises at least one open reading frame and wherein said at least one open reading frame is substituted by an ORF7.

6. The infectious clone of claim 1 wherein said recombinant nucleic acid comprises an insertion of at least one additional heterologous nucleic acid sequence.

7. The infectious clone of claim 6 wherein said heterologous nucleic acid sequence encodes an antigen.

8. The infectious clone of claim 1 wherein said recombinant nucleic acid comprises at least one open reading frame and wherein said at least one open reading frame has been modified by cloning techniques to effect a change in virulence and/or a change in serological immune response in vivo.